Single center retrospective analysis of association of hidradenitis suppurativa and chronic inflammatory bowel disease

Česká verzia

Authors: Vorčáková K. ¹; Ballová A. ¹; Madleňák M. ¹; Vorčák M. ²; Péč J. ¹
Authors place of work: Dermatovenerologická klinika JLF UK a UN Martin ¹; Radiologická klinika JLF UK a UN Martin ²
Published in the journal: Gastroent Hepatol 2021; 75(5): 438-443
Category: Original Article
doi: https://doi.org/10.48095/ccgh2021438

Summary

Introduction: Association between hidradenitis suppurativa (HS) and chronic inflammatory bowel disease (IBD) exists. Prevalence of IBD in patients with HS is not clear. The aim of this paper is to determine the prevalence of IBD in patients with HS, evaluate risk factors and possible phenotype of patients with HS and IBD. Methods: Single center retrospective analysis of 241 patients with HS was carried out and medical files were searched for inflammatory bowel disease accordingly. Epidemiologic data of HS were collected. Results: IBD had a prevalence of 5.8%. Out of this number 13 (92.9%) suffered from Crohn’s disease (CD) and 1 (7.1%) from ulcerative colitis (UC). Eight patients (57.1%) were referred to the dermatologist by gastroenterologist and in six patients (42.9%) history of IBD was detected by dermatologist during routine examination. Special phenotype of the disease associated with IBD was not confirmed. The study points out possible existence of common comorbidities and risk factors such as smoking and obesity. Discussion: Our study confirmed similar data like those available in literature, where strong association between CD and HS is present and weaker with UC and HS. Conclusion: The prevalence of IBD in HS patients (5.8%) however these patients do not have a distinct HS phenotype.

Keywords:

Ulcerative colitis – Crohn’s disease – comorbidities – risk factors – association – Hidradenitis suppurativa – chronic inflammatory bowel disease

Zdroje

1. Chen WT, Chi CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2019; 155 (9): 1022–1027. doi: 10.1001/jamadermatol.2019.0891.

2. Martorell A, Jfri A, Koster SB et al. Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. J Eur Acad Dermatol Venereol 2020; 34 (65): 1309–1318. doi: 10.1111/jdv.16 183.

3. Ostlere LS, Langtry JA, Mortimer PS et al. Hidradenitis suppurativa in Crohn’s disease. Br J Dermatol 1991; 125 (4): 384–386. doi: 10.1111/j.1365-2133.1991.tb14178.x.

4. Hein R, Köster I, Bollschweiler E et al. Prevalence of inflammatory bowel disease: estimates for 2010 and trends in Germany from a large insurance-based regional cohort. Scand J Gastroenterol 2014; 49 (11): 1325–1335. doi: 10.3109/00365521.2014.962605.

5. Rubin GP, Hungin AP, Kelly PJ et al. Inflammatory bowel disease: epidemiology and management in an English general practice population. Aliment Pharmacol Ther 2000; 14 (12): 1553– –1559. doi: 10.1046/j.1365-2036.2000.00886.x.

6. Büsch K, Ludvigsson JF, Ekström-Smedby K et al. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther 2014; 39 (1): 57–68. doi: 10.1111/apt.12528.

7. Jacobsen BA, Fallingborg J, Rasmussen HH et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978–2002. Eur J Gastroenterol Hepatol 2006; 18 (6): 601–606. doi: 10.1097/00042737-200606000-00005.

8. Deckers IE, Benhadou F, Koldijk MJ et al. Inflammatory bowel disease is associated with hidradenitis suppurativa: results from a multicenter cross-sectional study. J Am Acad Dermatol 2017; 76 (1): 49–53. doi: 10.1016/j.jaad.2016.08.031.

9. Shalom G, Freud T, Yakov GB et al. Hidradenitis suppurativa and inflammatory bowel disease: a cross-sectional study of 3,207 patients. J Invest Dermatol 2016; 136 (8): 1716–1718. doi: 10.1016/j.jid.2016.04.003.

10. Garg A, Hundal J, Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa a population-based analysis in the United States. JAMA Dermatol 2018; 154 (7): 814–818. doi: 10.1001/jamadermatol.2018.0878.

11. Egeberg A, Jemec GB, Kimball AB et al. Prevalence and risk of inflammatory bowel disease in patients with hidradenitis suppurativa. J Invest Dermatol 2017; 137 (5): 1060–1064. doi: 10.1016/j.jid.2016.11.040.

12. Lukach AJ, Saul MI, Ferris LK et al. Risk factors for hidradenitis suppurativa in patients with inflammatory bowel disease. Dig Dis Sci 2018; 63 (3): 755–760. doi: 10.1007/s10620-018-4919-5.

13. Scheinfeld N. Diseases associated with hidranitis suppurativa: part 2 of a series on hidradenitis. Dermatol Online J 2013; 19 (6): 18558.

14. Lee M, Krishnamurthy J, Susi A et al. Association of autism spectrum disorders and inflammatory bowel disease. J Autism Dev Disord 2018; 48 (5): 1523–1529. doi: 10.1007/s10803-017-3409-5.

15. Souto-Rodríguez R, Barreiro-de-Acosta M, Domínguez-Muñoz JE. Down’s syndrome and inflammatory bowel disease: is there a real link? Rev Esp Enferm Dig 2014; 106 (3): 220–222.

16. Bernstein CN, Hitchon CA, Walld R et al. Increased burden of psychiatric disorders in inflammatory bowel disease. Inflamm Bowel Dis 2019; 25 (2): 360–368. doi: 10.1093/ibd/izy235.

17. van der Zee HH, Horvath B, Jemec GB et al. The association between hidradenitis suppurativa and Crohn’s disease: in search of the missing pathogenic link. J Invest Dermatol 2016; 136 (9): 1747–1748. doi: 10.1016/j.jid.2016.05.102.

18. Monnier L, Dohan A, Amara N et al. Anoperineal disease in Hidradenitis Suppurativa : MR imaging distinction from perianal Crohn’s disease. Eur Radiol 2017; 27 (10): 4100–4109. doi: 10.1007/s00330-017-4776-1.

19. Schlapbach C, Hänni T, Yawalkar N et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65 (4): 790–798. doi: 10.1016/j.jaad.2010.07.010.

20. Duerr RH, Taylor KD, Brant SR et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006; 314 (5804): 1461–1463. doi: 10.1126/ science.1135245.

21. Yang Y, Owyang C, Wu GD. East Meets West: the increasing incidence of inflammatory bowel disease in Asia as a paradigm for environmental effects on the pathogenesis of immune-mediated disease. Gastroenterology 2016; 151 (6): e1–e5. Doi: 10.1053/j.gastro.2016.10. 034.

22. Schwarz A, Bruhs A, Schwarz T. The short-chain fatty acid sodium butyrate functions as a regulator of the skin immune system. J Invest Dermatol 2017; 137 (4): 855–864. doi: 10.1016/ j.jid.2016.11.014.

23. O’Neill CA, Monteleone G, McLaughlin JT et al. The gut-skin axis in health and disease: a paradigm with therapeutic implications. Bioessays 2016; 38 (11): 1167–1176. doi: 10.1002/bies.201600008.

24. Vorčáková K, Horáková M, Péč J. Anti-TNF alpha-induced immune-mediated skin adverse reactions resolved by switching to ustekinumab. Gastroent Hepatol 2019; 73 (6): 496–500. doi: 10.14735/amgh2019496.